Castration-resistant prostate cancer market to reach $9.5 billion by 2020
The global castration-resistant prostate cancer (CRPC) therapeutics market is forecast to generate revenue of $9.5 billion by 2020, according to a report by Allied Market Research.
This would register a compound annual growth rate of 9.1% from 2015 to 2020, with the hormonal therapy segment leading the way at four-fifths of global market value in 2014 and sustaining this market position through to 2020.
The global market for CPRC therapeutics has experienced high growth in the past few years, and would continue to grow consistently due to high unmet clinical need. There is a large amount of drugs in the pipeline, but higher patient awareness is also driving the market growth during the forecast period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze